Weight Management
Semaglutide
Starting at
$249/mo
Physician-supervised compounded GLP-1 therapy for weight management.
- Route
- Weekly injection
- Frequency
- Once weekly
- Access
- Prescription only
- Billing
- Monthly, cancel anytime
What it is
Semaglutide is a GLP-1 receptor agonist studied for weight management and blood-sugar control. The compounded preparation is prescribed by a U.S.-licensed physician and prepared and dispensed by a licensed compounding pharmacy.
The compounded preparation has not undergone equivalent finished-product efficacy testing; brand-name trial results should not be assumed to transfer one-for-one.
Semaglutide clinical details
Semaglutide is a 94% structural analog of human GLP-1 with key amino acid substitutions at positions 8 and 34 that confer resistance to DPP-4 enzymatic degradation. It binds to and activates GLP-1 receptors in the hypothalamic arcuate nucleus, stimulating POMC/CART neurons (which promote satiety) while inhibiting NPY/AgRP neurons (which drive hunger). In the gastrointestinal tract, it slows gastric emptying by reducing vagal-mediated motility, prolonging the feeling of fullness after meals. It also acts on pancreatic beta cells to enhance glucose-dependent insulin secretion and suppress glucagon release from alpha cells. The albumin-binding fatty acid side chain extends the half-life to approximately 7 days, enabling once-weekly dosing.
The clinical-trial evidence for semaglutide weight management was developed for the brand-name finished product, not for any compounded preparation. The STEP trial program studied brand-name semaglutide across multiple populations (STEP 1 in adults with obesity; STEP 2 in patients with type 2 diabetes; STEP 3 with intensive behavioral therapy; STEP 4 on discontinuation; STEP 5 extended-duration data). The SELECT cardiovascular outcomes trial studied the brand-name product in overweight or obese adults without diabetes. The compounded preparation dispensed by the partner pharmacy has not undergone equivalent finished-product efficacy or safety testing; published brand-name trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from the compounded preparation. Your physician will discuss realistic expectations at consultation.
- GLP-1 receptor agonists have been studied for weight management
- Reduced appetite and food cravings through central-nervous-system signaling
- Improved glycemic control with lower fasting blood glucose and HbA1c (studied in the brand-name product)
- Cardiovascular risk reduction has been studied in the brand-name product (SELECT trial)
- Designed for adherence with a consistent weekly schedule set by your physician
- Nausea (most common, typically decreases over 4-8 weeks)
- Diarrhea or constipation
- Vomiting, particularly during dose escalation
- Abdominal pain or bloating
- Headache
- Fatigue
- Injection site reactions (redness, swelling)
- Decreased appetite (therapeutic effect but can be pronounced)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide or any excipients
- History of pancreatitis
- Pregnancy or planning to become pregnant (discontinue at least 2 months before conception)
- Breastfeeding
- Severe gastroparesis or gastrointestinal disease
- End-stage renal disease (eGFR below 15 mL/min)
- Insulin or sulfonylureas - increased risk of hypoglycemia; dose adjustment may be needed
- Oral contraceptives - delayed gastric emptying may reduce absorption; consider non-oral methods
- Warfarin - monitor INR more frequently during initiation and dose changes
- Levothyroxine - absorption may be affected; take thyroid medication on an empty stomach
- Oral medications with narrow therapeutic index - monitor levels due to altered absorption timing
Follow the storage instructions provided by your pharmacy and on the medication label. Do not use if the solution appears cloudy, discolored, or contains particles.
Semaglutide frequently asked questions
Patient experience varies. Many people begin noticing reduced appetite and early weight changes within the first few weeks of physician-supervised therapy; the largest weight changes typically occur over several months in brand-name clinical trials. The compounded preparation has not undergone equivalent finished-product testing and outcomes cannot be guaranteed. Individual results vary based on starting weight, adherence, and lifestyle factors.
Brand-name trial data (STEP 4) showed that patients who discontinued semaglutide regained a portion of their lost weight over the following months, reflecting that GLP-1 therapy addresses biological drivers of weight regain that persist after weight loss. Long-term planning, including any maintenance or structured tapering strategy, is decided patient-by-patient at consultation alongside sustained lifestyle modifications. Outcomes from the compounded preparation are not guaranteed to match brand-name trial data.
Compounded semaglutide uses the same active molecule as the brand-name finished products but is prepared by a licensed compounding pharmacy. Compounded medications are not interchangeable with the brand-name medications they may reference. All Pep Club pharmacy partners are state-licensed and follow USP 797 sterile-compounding standards including potency and sterility testing on every batch.
Yes, semaglutide was originally developed for type 2 diabetes management (marketed as Ozempic). However, if you are already taking diabetes medications - especially insulin or sulfonylureas - your physician will need to coordinate those medications to prevent hypoglycemia (low blood sugar). During your Pep Club consultation, disclose all current medications so your physician can create a safe, coordinated treatment plan.
Most insurance plans do not cover compounded medications. The Pep Club uses transparent monthly subscription pricing for each medication, billed independently of your biomarker plan - current prices are listed on the pricing page. Itemized receipts are provided for HSA/FSA use or out-of-network reimbursement requests.
Availability
Available where The Pep Club has a licensed physician and a licensed pharmacy partner. See the state availability page for the current list.
Also in the formulary
Ready when you are.
A two-minute eligibility check tells you if we ship to your state. A licensed physician takes it from there.
Compounded preparation
This is a compounded preparation prepared by a licensed compounding pharmacy under U.S.-licensed physician supervision. The active pharmaceutical ingredient also appears in brand-name finished products; the compounded preparation is not interchangeable with those brand-name medications and actual product appearance and labeling may differ. Patients are screened and supervised by U.S.-licensed physicians throughout treatment.